Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, Australia.
Department of Otolaryngology, Head and Neck Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ann Surg Oncol. 2018 Jun;25(6):1730-1736. doi: 10.1245/s10434-018-6340-x. Epub 2018 Jan 19.
The American Joint Committee on Cancer (AJCC) uses the same nodal staging system for cutaneous and mucosal squamous cell carcinoma of the head and neck in its 8th edition (AJCC 8) despite differences in the etiology, risk factors, and clinical behavior of the two diseases. This study aims to evaluate the performance of the AJCC 8 nodal staging system by direct comparison of cutaneous (cSCC) versus oral squamous cell carcinoma (oSCC) patients.
Patients with metastatic cSCC (N = 382) and oSCC (N = 325) were identified from a prospective database (years 1987-2016). Multivariable analysis was performed using Cox proportional hazards competing risk model. To assess staging system performance, an explained variation measure (proportion of variation explained, PVE) as well as a discrimination measure (Harrell's concordance index, C-index) were used.
Inclusion of extranodal extension (ENE) in AJCC 8 increased the proportion of patients in N3b category (48.7% in cSCC, 40.3% in oSCC). AJCC 8 stratified poorly with regards to risk of death from cSCC and oSCC and showed limited monotonicity of the nodal categories. Estimates of model performance revealed modest predictive capacity for overall survival (OS) and disease-specific survival (DSS) in oSCC (Harrell's C of 0.66 in both) and weak predictive capacity in cSCC (Harrell's C of 0.58 and 0.61, respectively).
The AJCC 8 nodal staging system performs poorly in terms of stratifying survival by N category, especially in cSCC. The data indicate that cSCC merits an independent nodal staging system from that for mucosal SCC.
尽管皮肤和黏膜鳞状细胞癌的病因、危险因素和临床行为存在差异,但美国癌症联合委员会 (AJCC) 在其第 8 版中仍对头颈部皮肤和黏膜鳞状细胞癌使用相同的淋巴结分期系统。本研究旨在通过直接比较皮肤鳞状细胞癌 (cSCC) 和口腔鳞状细胞癌 (oSCC) 患者,评估 AJCC 8 淋巴结分期系统的性能。
从前瞻性数据库 (1987 年至 2016 年) 中确定了转移性 cSCC (N=382) 和 oSCC (N=325) 患者。使用 Cox 比例风险竞争风险模型进行多变量分析。为了评估分期系统的性能,使用了一个解释变异量的度量(变异解释比例,PVE)以及一个区分度量(Harrell 一致性指数,C 指数)。
AJCC 8 将额外的淋巴结外延伸 (ENE) 纳入其中,增加了 N3b 期患者的比例(cSCC 中为 48.7%,oSCC 中为 40.3%)。AJCC 8 对 cSCC 和 oSCC 的死亡风险分层较差,并且节点类别单调有限。模型性能的估计显示,AJCC 8 对总体生存率 (OS) 和疾病特异性生存率 (DSS) 的预测能力适中(在 oSCC 中 Harrell 的 C 分别为 0.66),在 cSCC 中的预测能力较弱(Harrell 的 C 分别为 0.58 和 0.61)。
就 N 分期分层生存而言,AJCC 8 淋巴结分期系统表现不佳,尤其是在 cSCC 中。数据表明,cSCC 需要一个独立于黏膜 SCC 的淋巴结分期系统。